Unlocking smooth drug delivery
Duodopa: Provides a smooth, consistent, adjustable delivery of levodopa (plus carbidopa) directly into the jejunum or duodenum via a PEG/J tube1
- Disrupted transit of levodopa is a common feature of Parkinson's disease and can make control unpredictable. Duodopa has a way round it1,6
- For eligible patients where the levodopa works but the delivery doesn't, Duodopa can unlock disease control1,2
In an open-label study Duodopa offered clinically
meaningful improvements in motor function vs. baseline2
In this study, patients receiving the levodopa-carbidopa intestinal gel experienced significant improvements in functioning as early as 4 weeks after beginning therapy, which was maintained throughout the study2
Unlocking reassurance with long-term tolerability
An open-label study shows Duodopa offers a well understood adverse event profile2
For the majority of patients AEs were mild (19%) or moderate (44%) and transient2
Low withdrawal rate (8%) due to AEs, most commonly due to complication of insertion device2
Unlocking a reduced burden of care for caregivers4
In an open-label study caregivers indicated improvements in the burden of care when caring for patients on Duodopa therapy (n=7)4
Adapted from Santos-Garcia et al. 2012.
Caregivers indicate improvements in the strain they experience when caring for patients on Duodopa therapy (n=7)4
Adapted from Santos-Garcia et al. 2012. Open-label study of seven patients with advanced PD treated with Duodopa. All patients had motor fluctuations and dyskinesia prior to Duodopa. Mean follow up with Duodopa therapy 31.4 ±7.9 months.